14-Jan-2026
Ipsen rises on FDA breakthrough therapy status for blood cancer therapy
Seeking Alpha News (Wed, 14-Jan 6:57 AM ET)
Leerink Partners Sticks to Their Buy Rating for AbbVie (ABBV)
TipRanks (Wed, 14-Jan 3:36 AM ET)
AbbVie Gets Tariff Relief, Pledges $100 Billion, Lower Prices For Key Medicines
Benzinga (Tue, 13-Jan 8:09 AM ET)
AbbVie (ABBV) Commits $100B in U.S. Investment, Inks Deal with Trump to Avoid Tariffs
TipRanks (Tue, 13-Jan 2:25 AM ET)
AbbVie secures tariff relief in drug pricing deal, pledges $100B investment
Seeking Alpha News (Mon, 12-Jan 11:00 PM ET)
AbbVie and Trump Administration Reach Agreement to Improve Access and Affordability for Americans
PRNewswire (Mon, 12-Jan 6:31 PM ET)
AbbVie’s ABBV-932 Bipolar Depression Trial Reaches Completion: What Investors Should Watch Next
TipRanks (Mon, 12-Jan 11:30 AM ET)
AbbVie in up to $5.6B deal with RemeGen for bispecific antibody for solid tumors
Seeking Alpha News (Mon, 12-Jan 8:50 AM ET)
PRNewswire (Mon, 12-Jan 7:30 AM ET)
AbbVie to buy Arizona manufacturing facility from West Pharmaceutical
Seeking Alpha News (Mon, 12-Jan 6:09 AM ET)
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
Abbvie trades on the NYSE stock market under the symbol ABBV.
As of January 14, 2026, ABBV stock price climbed to $221.89 with 6,697,540 million shares trading.
ABBV has a beta of 0.28, meaning it tends to be less sensitive to market movements. ABBV has a correlation of 0.04 to the broad based SPY ETF.
ABBV has a market cap of $391.95 billion. This is considered a Mega Cap stock.
Last quarter Abbvie reported $16 billion in Revenue and $1.86 earnings per share. This beat revenue expectation by $189 million and exceeded earnings estimates by $.08.
In the last 3 years, ABBV traded as high as $244.81 and as low as $130.96.
The top ETF exchange traded funds that ABBV belongs to (by Net Assets): VTI, VOO, IVV, SPY, VTV.
ABBV has outperformed the market in the last year with a return of +29.3%, while the SPY ETF gained +20.0%. However, in the most recent history, ABBV shares have underperformed the stock market with its stock returning -2.9% in the last 3 month period and -3.4% for the last 2 week period, while SPY has returned +4.4% and +0.5%, respectively.
ABBV support price is $217.18 and resistance is $224.33 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ABBV shares will trade within this expected range on the day.